Investing
Proceeds from Sale of Seagen Inc. Common Stock
MetLife Proceeds from Sale of Seagen Inc. Common Stock decreased by 81.8% to $8.00M in Q1 2026 compared to the prior quarter. Year-over-year, this metric declined by 11.1%, from $9.00M to $8.00M. Over 4 years (FY 2021 to FY 2025), Proceeds from Sale of Seagen Inc. Common Stock shows a downward trend with a -33.3% CAGR.
Analysis
StatementCash Flow Statement
SectionInvesting
First reportedQ1 2019
Last reportedQ1 2026May 7, 2026
Metric ID:
mrk_proceeds_from_sale_of_seagen_stockHistorical Data
20 periods
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $179.00M | $141.00M | $232.00M | $384.00M | $89.00M | $148.00M | $252.00M | $61.00M | $866.00M | $80.00M | $11.00M | $37.00M | $7.00M | $45.00M | $69.00M | $9.00M | $45.00M | $42.00M | $44.00M | $8.00M |
| QoQ Change | — | -21.2% | +64.5% | +65.5% | -76.8% | +66.3% | +70.3% | -75.8% | >999% | -90.8% | -86.3% | +236.4% | -81.1% | +542.9% | +53.3% | -87.0% | +400.0% | -6.7% | +4.8% | -81.8% |
| YoY Change | — | — | — | — | -50.3% | +5.0% | +8.6% | -84.1% | +873.0% | -45.9% | -95.6% | -39.3% | -99.2% | -43.8% | +527.3% | -75.7% | +542.9% | -6.7% | -36.2% | -11.1% |
Range$7.00M – $866.00M
CAGR-48.0%
Avg YoY Growth+85.6%
Median YoY Growth-37.8%
Proceeds from Sale of Seagen Inc. Common Stock at Other Companies
Frequently Asked Questions
- What is MetLife's proceeds from sale of seagen inc. common stock?
- MetLife (MET) reported proceeds from sale of seagen inc. common stock of $8.00M in Q1 2026.
- How has MetLife's proceeds from sale of seagen inc. common stock changed year-over-year?
- MetLife's proceeds from sale of seagen inc. common stock decreased by 11.1% year-over-year, from $9.00M to $8.00M.
- What is the long-term trend for MetLife's proceeds from sale of seagen inc. common stock?
- Over 4 years (2021 to 2025), MetLife's proceeds from sale of seagen inc. common stock has grown at a -33.3% compound annual growth rate (CAGR), from $708.00M to $140.00M.